IFNG and acute myeloid leukemia: Further, we assessed IFNγ concentrations in the sera of 43 consecutively collected, newly diagnosed AML patients that present to our center and observed elevated level of IFNγ in sera of 67.4% of patients that exceeded those typical of the healthy reference group, which fortifies the notion that IFNγ is dysregulated at the time of diagnosis in AML patients and underscores the need for further exploration into its potential clinical implications and therapeutic utility (Fig. 1F).